{"organizations": [], "uuid": "dfca68c2be0540a20aa3356df881c868102bd05d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180221.html", "section_title": "Archive News &amp; Video for Wednesday, 21 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/viralytics-ma-merck-co/merck-to-buy-viralytics-for-394-mln-to-boost-immuno-oncology-idUSL8N1QB2B3", "country": "US", "domain_rank": 408, "title": "Merck to buy Viralytics for $394 mln to boost immuno-oncology", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.643, "site_type": "news", "published": "2018-02-21T17:26:00.000+02:00", "replies_count": 0, "uuid": "dfca68c2be0540a20aa3356df881c868102bd05d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/viralytics-ma-merck-co/merck-to-buy-viralytics-for-394-mln-to-boost-immuno-oncology-idUSL8N1QB2B3", "ord_in_thread": 0, "title": "Merck to buy Viralytics for $394 mln to boost immuno-oncology", "locations": [], "entities": {"persons": [{"name": "louise heavens", "sentiment": "none"}, {"name": "ben hirschler", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "merck & co", "sentiment": "negative"}, {"name": "merck", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 21 (Reuters) - U.S. drugmaker Merck & Co, already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its drug pipeline.\nMerck will pay 1.75 Australian dollars per share for the Sydney-based biotech company, which uses viruses to infect and kill cancer cells. That represents a premium of 160 percent to the average stock price over the past month. ($1 = 1.2740 Australian dollars) (Reporting by Ben Hirschler, editing by Louise Heavens)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-21T17:26:00.000+02:00", "crawled": "2018-02-22T18:20:22.011+02:00", "highlightTitle": ""}